Canaccord Genuity Reiterates Buy Rating for ACADIA Pharmaceuticals
Canaccord Genuity maintains its buy rating for ACADIA Pharmaceuticals with a $36 price target, a 41.20% upside from the current price.
Key Points
- Canaccord Genuity reiterated its buy rating for ACADIA Pharmaceuticals with a $36 price target on June 29, 2026.
- Canaccord Genuity's $36 price target implies 41.20% upside from ACADIA Pharmaceuticals Inc.'s ($ACAD) current $25.50 share price.
- ACADIA's shares traded at $25.32 on NasdaqGS with a market cap of $4.34 billion and a P/E ratio of 11.46.
- Major institutional holders like BlackRock and State Street have increased their stakes in ACADIA Pharmaceuticals.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Canaccord Genuity has reiterated its buy rating for ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD) with a price target of $36. This update came on June 29, 2026, from analyst Sumant Kulkarni. ACADIA's shares were trading around $25.32 on Monday.
Canaccord Genuity vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in ACADIA Pharmaceuticals
Several institutional investors have been active in ACADIA Pharmaceuticals recently. BlackRock, Inc. increased its holdings by 795,469 shares, bringing its total to 21,550,921 shares valued at approximately $479.7 million, marking a 3.8% increase. State Street Corp also bolstered its position by 422,038 shares, resulting in 8,332,771 shares worth about $185.5 million, a 5.3% rise. Vanguard Portfolio Management LLC opened a new position with 8,671,645 shares valued at $193.0 million.
ACADIA Pharmaceuticals Inc. Stock Down 12.4%
Shares of ACADIA Pharmaceuticals traded near $25.32 on Monday. The company has a market capitalization of about $4.34 billion and a P/E ratio of 11.46. Its beta is 0.83, indicating lower volatility compared to the market. Over the past year, the stock has moved between $19.69 and $28.35. The 50-day moving average is $21.85, while the 200-day moving average stands at $23.24.
$ACAD price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its latest earnings report, ACADIA Pharmaceuticals reported revenue of $1.10 billion, reflecting a growth rate of 9.7%. The company achieved a net margin of 34.3% and a return on equity of 37.3%. Its earnings per share (EPS) stood at $2.21. The next earnings release is scheduled for August 5, 2026.
Insider Buying and Selling at ACADIA Pharmaceuticals Inc.
Recent insider activity at ACADIA Pharmaceuticals includes several transactions on May 29, 2026. Baker Bros. Advisors LP acquired 32,008 shares, while Jonathan Poole and James Daly each bought 16,004 shares. Laura Brege purchased 8,107 shares. These transactions were not part of a planned trading program.
Analysts Set New Price Targets
On June 29, 2026, Citigroup maintained its buy rating for ACADIA Pharmaceuticals with a $35 price target. Canaccord Genuity also maintained its buy rating and set a target of $36. The consensus among analysts is a buy rating, with a mean price target of $32 based on 20 opinions.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company based in San Diego, California. It focuses on developing and commercializing medicines for neurological and rare diseases in North America. The company is known for its product NUPLAZID, used to treat Parkinson's disease psychosis, and DAYBUE, for Rett syndrome. ACADIA is led by CEO Catherine E. Owen Adams and employs 796 people.
Bottom Line
Canaccord Genuity's reaffirmation of its buy rating for ACADIA Pharmaceuticals highlights continued confidence in the company's prospects. Investors track these analyst updates closely as they can influence market perceptions. Remember, these ratings are based on past data and might not reflect current conditions.
Get ACADIA Pharmaceuticals Inc. alerts
New 13F filings, insider trades, and analyst moves on $ACAD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.